Want to see SION full AI Analyst Report?
SION Stock Chart & Stats
$43.54
$0.55(1.26%)
At close: 4:00 PM EST
$43.54
$0.55(1.26%)
Day’s Range― - ―
52-Week Range$13.81 - $48.45
Previous CloseN/A
Volume33.51K
Average Volume (3M)397.51K
Market Cap
$1.99B
Enterprise Value$1.60B
Total Cash (Recent Filing)$216.15M
Total Debt (Recent Filing)$8.38M
Price to Earnings (P/E)―
Beta1.18
Next Earnings
Aug 17, 2026EPS Estimate
-0.65Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.93
Shares Outstanding45,150,330
10 Day Avg. Volume390,796
30 Day Avg. Volume397,515
Financial Highlights & Ratios
PEG Ratio-0.64
Price to Book (P/B)5.36
Price to Sales (P/S)0.00
P/FCF Ratio-24.66
Enterprise Value/Market Cap0.81
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-3.54K
Enterprise Value/Ebitda-19.78
Forecast
1Y Price Target
$51.71Price Target Upside18.77% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
EPS Forecast (FY)-2.58
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strengthened Balance SheetPositive shareholders' equity of $306.8M after prior negative equity is a durable improvement in capital structure. It expands funding flexibility and reduces insolvency risk, giving management a longer runway to progress clinical programs without immediate financing pressure.
Focused CFTR Therapeutic StrategyA clear, focused therapeutic mandate on CFTR dysfunction creates a durable strategic orientation. Targeting unmet subpopulations not helped by existing treatments can yield differentiated products and clearer clinical development paths, aiding long-term value creation if trials succeed.
Governance And Auditor ContinuityReelection of directors and ratification of Deloitte signal shareholder backing and continuity in governance and financial oversight. Stable leadership and consistent external audit support reduce execution risk for multi-year clinical and financing programs.
Bears Say
Pre-revenue With Widening LossesBeing pre-revenue with widening operating losses is a durable constraint: without product revenue the company must rely on financing. Rising R&D and operating deficits increase required capital raises, heightening dilution risk and making long-term viability contingent on clinical success.
Heavy, Persistent Cash BurnSustained negative operating and free cash flow (about -$66M in 2025) is a structural concern for capital allocation. Persistent burn narrows strategic optionality, forces external financing, and increases dependency on capital markets timing regardless of near-term market sentiment.
Negative Return On EquityA -24.5% return on equity after restoring positive equity indicates the company currently destroys shareholder capital. This persistent negative ROE reflects weak unit economics and raises questions about long-term value creation absent successful product milestones.
Sionna Therapeutics, Inc. News
SION FAQ
What was Sionna Therapeutics, Inc.’s price range in the past 12 months?
Sionna Therapeutics, Inc. lowest stock price was $13.81 and its highest was $48.45 in the past 12 months.
What is Sionna Therapeutics, Inc.’s market cap?
Sionna Therapeutics, Inc.’s market cap is $1.99B.
When is Sionna Therapeutics, Inc.’s upcoming earnings report date?
Sionna Therapeutics, Inc.’s upcoming earnings report date is Aug 17, 2026 which is in 43 days.
How were Sionna Therapeutics, Inc.’s earnings last quarter?
Sionna Therapeutics, Inc. released its earnings results on May 12, 2026. The company reported -$0.6 earnings per share for the quarter, missing the consensus estimate of -$0.514 by -$0.086.
Is Sionna Therapeutics, Inc. overvalued?
According to Wall Street analysts Sionna Therapeutics, Inc.’s price is currently Undervalued.
Does Sionna Therapeutics, Inc. pay dividends?
Sionna Therapeutics, Inc. does not currently pay dividends.
What is Sionna Therapeutics, Inc.’s EPS estimate?
Sionna Therapeutics, Inc.’s EPS estimate is -0.65.
How many shares outstanding does Sionna Therapeutics, Inc. have?
Sionna Therapeutics, Inc. has 45,150,330 shares outstanding.
What happened to Sionna Therapeutics, Inc.’s price movement after its last earnings report?
Sionna Therapeutics, Inc. reported an EPS of -$0.6 in its last earnings report, missing expectations of -$0.514. Following the earnings report the stock price went down -10.903%.
Which hedge fund is a major shareholder of Sionna Therapeutics, Inc.?
Currently, no hedge funds are holding shares in SION
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sionna Therapeutics, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$51.71 (18.77% Upside)
$51.71 (18.77% Upside)
Blogger Sentiment
Bullish
SION Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 527.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 3.8%
Last 30 Days ▲ 6.9%
Last 30 Days ▲ 6.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
110.78%
12-Months-Change
Fundamentals
Return on Equity
-27.31%
Trailing 12-Months
Asset Growth
-17.48%
Trailing 12-Months
Company Description
Sionna Therapeutics, Inc.
Operating as a biopharmaceutical company, Sionna Therapeutics, Inc. is dedicated to transforming the treatment landscape for individuals with cystic fibrosis. This is achieved by developing innovative medicines designed to restore the normal function of the cystic fibrosis transmembrane conductance regulator.
SION Stock 12 Month Forecast
Average Price Target
$51.71
▲(18.77% Upside)
Technical Analysis
Stoke Therapeutics
―
Vir Biotechnology
―
Immatics
―
Tango Therapeutics
―
Amylyx Pharmaceuticals Inc
―
Ownership Overview
34.50% Insiders
9.90% Mutual Funds
13.30% Other Institutional Investors
36.38% Public Companies and
Individual Investors